Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug duo tested in fight against spreading prostate cancer

NCT ID NCT03674814

Summary

This early-stage trial tested the safety and dosing of a new two-drug combination for men with advanced prostate cancer that has spread and is no longer responding to standard hormone-blocking treatments. The study combined an existing prostate cancer drug (enzalutamide) with an experimental drug (relacorilant) to see if they work better together. Researchers enrolled 42 participants to find the safest and most effective dose for future testing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University Of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.